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ABSTRACT
Compound-induced liver injury leading to fibrosis remains a challenge for the development of an Adverse Outcome
Pathway useful for human risk assessment. Latency to detection and lack of early, systematically detectable biomarkers
make it difficult to characterize the dynamic and complex intercellular interactions that occur during progressive liver
injury. Here, we demonstrate the utility of bioprinted tissue constructs comprising primary hepatocytes, hepatic stellate
cells, and endothelial cells to model methotrexate- and thioacetamide-induced liver injury leading to fibrosis. Repeated,
low-concentration exposure to these compounds enabled the detection and differentiation of multiple modes of liver
injury, including hepatocellular damage, and progressive fibrogenesis characterized by the deposition and accumulation
of fibrillar collagens in patterns analogous to those described in clinical samples obtained from patients with fibrotic liver
injury. Transient cytokine production and upregulation of fibrosis-associated genes ACTA2 and COL1A1 mimics hallmark
features of a classic wound-healing response. A surge in proinflammatory cytokines (eg, IL-8, IL-1b) during the early
culture time period is followed by concentration- and treatment-dependent alterations in immunomodulatory and
chemotactic cytokines such as IL-13, IL-6, and MCP-1. These combined data provide strong proof-of-concept that 3D
bioprinted liver tissues can recapitulate drug-, chemical-, and TGF-b1-induced fibrogenesis at the cellular, molecular, and
histological levels and underscore the value of the model for further exploration of compound-specific fibrogenic
responses. This novel system will enable a more comprehensive characterization of key attributes unique to fibrogenic
agents during the onset and progression of liver injury as well as mechanistic insights, thus improving compound risk
assessment.
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Chronic liver injury progressing to fibrosis and liver failure can re-
sult from a wide range of insults including drug or chemical ex-
posure, metabolic disease, alcoholism, or viral infection, and is a
major health burden worldwide with 2% of all deaths attributable
to liver cirrhosis (Lozano et al., 2012; Murray et al., 2012). Whereas
the major precipitating factors underlying drug- and chemical-
induced fibrosis have been gleaned from animal models, the key
initiating and series of adaptive events that perpetuate this re-
sponse, especially in humans, are still not well understood.
Regardless of etiology, progressive fibrotic liver injury is
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orchestrated by complex intercellular interactions among hepato-
cytes (HCs), endothelial cells (ECs), hepatic stellate cells (HSCs),
Kupffer cells (KCs), and recruited inflammatory cells (Bataller and
Brenner, 2005).
Animal models of chronic liver injury with fibrosis partially re-
capitulate the human condition, but may fail to provide robust
human translation due to species differences in metabolism, injury
response, and capacity/mechanisms of repair and regeneration (Liu
et al., 2013). Cell culture has been used as a surrogate to dissect the
mechanistic details underlying HC dysfunction and fibrogenic out-
come; however, conventional two-dimensional (2D), cell-based
hepatic model systems do not reliably recapitulate liver structure,
function, and its inherent multicellular architecture (LeCluyse et al.,
2012). This is largely due to the absence of non-parenchymal cells
(NPCs) relevant to liver injury and fibrogenic response. HSCs are
recognized key effectors in the development and progression of
hepatic fibrosis (Puche et al., 2013) however, they also help to define
the molecular and structural microenvironment of the parenchy-
mal compartment and space of Disse via the production of soluble
and insoluble cues, including growth factors, inflammatory cyto-
kines, and deposition of extracellular matrix (ECM) (Friedman,
2008). These microenvironments mediate requisite gene expression
patterns for metabolic homeostasis, cellular differentiation, and
maturation (Guillouzo et al., 1993; Rogiers and Vercruysse, 1993) and
thus modulate the liver’s response to both acute and chronic injury.
These observations suggest that current in vitro models used to
evaluate potential fibrogenic agents lack fundamental cellular com-
ponents that may moderate or exacerbate hepatocellular injury, an
event strongly associated with the initiation of fibrogenesis
(Canbay et al., 2004). Furthermore, the appearance and progression
of basic fibrogenic features such as inflammation, tissue remodel-
ing, collagen accumulation, and compensatory hepatocellular re-
generation are best detected and interpreted in the context of a
three-dimensional (3D) tissue environment. As such, these compo-
nents are required in order to fully understand quantitative and
temporal relationships underlying complex processes, such as fi-
brosis arising from chronic liver injury.
The recent availability of bioprinted human liver tissue models
that incorporate both parenchymal (ie, HCs) and NPCs (ie, HSCs and
ECs) in a 3D context has created the opportunity to examine pro-
gressive liver injury in response to known pro-fibrotic modulators
and compounds (Nguyen et al., 2016). In this study, we utilized this
novel model system to establish conditions for monitoring tissue
responses after treatment with fibrogenic agents, including trans-
forming growth factor-b1 (TGF-b1), and prototype fibrogenic com-
pounds methotrexate (MTX), and thioacetamide (TAA). Significant
concentration- and time-dependent elevations of lactate dehydro-
genase (LDH) were observed for both MTX and TAA and were
accompanied by the acquisition of a fibrogenic phenotype as sup-
ported by tissue remodeling, NPC migration/activation, histologic
evidence of collagen deposition, transient elevations in proinflam-
matory, immunomodulatory, and chemotactic cytokines, and the
expression of ACTA2 and COL1A1. In comparison, treatment with
TGF-b1, a known pro-fibrogenic cytokine, yielded moderate fibrotic
change in the tissue with little evidence of hepatocellular damage.
Taken together, these data demonstrate the utility of novel 3D bio-
printed tissues to further evaluate compound-induced liver fibrosis
in a more defined and systematic fashion.
MATERIALS AND METHODS
Tissue production
Three-dimensional bioprinted liver tissues were manufactured
by Organovo (San Diego, California) using primary cryopreserved
human HCs (Life Technologies, Carlsbad, California), HSCs
(ScienCell, Carlsbad, California), and human umbilical vein ECs
(Becton Dickinson, Tewksbury, Massachusetts), using patented
protocols (U.S. Patents 8,241,905 B2; 8,852,932; 9,222,932 B2;
9,222,932 B2) as described previously (Forgacs et al., 2012, 2014;
Murphy et al., 2015; Nguyen et al., 2016; Shepherd et al., 2015).
Each commercial cell supplier provides assurances that the cells
come from tissues collected in compliance with applicable laws
and provided based on informed consent by the donors. Briefly,
HSCs and ECs were cultured prior to tissue fabrication and cryo-
preserved HCs were thawed and prepared for use according to
the manufacturer’s instructions. Separate bio-inks comprising
parenchymal cells (100% cellular paste, generated via compac-
tion) or NPCs (150e6 cells/mL formulated in NovoGel 2.0
Hydrogel) were prepared and loaded into separate heads of the
NovoGen Bioprinter platform (Organovo) housed within a
standard biosafety cabinet (Forgacs et al., 2012, 2014; Jakab et al.,
2008; Murphy, et al., 2015; Nguyen, et al., 2016; Shepherd, et al.,
2015). An automated computer script was then executed to
precisely deposit the bio-inks in a two-compartment planar
geometry onto the membranes of standard 24-well 0.4 mm trans-
well membrane inserts (Corning, Tewksbury, Massachusetts) via
continuous deposition, with NPCs comprising the border regions
of each compartment and HCs filling each compartment such
that the cell ratios roughly approximated physiologic ratios and
the final tissue thickness was approximately 500 mm (Murphy
and Atala, 2014). Following fabrication, the tissues were cultured
in DMEM supplemented with Primary Hepatocyte Maintenance
Supplements (Life Technologies, Carlsbad, California) and EGM-2
(Lonza, Basel, Switzerland) and maintained in a 37 C incubator
under humidified atmospheric conditions with 5% CO2. Liver tis-
sues were allowed to coalesce into tissue-like structures for a
minimum of three days with the daily replacement of medium
prior to treatment with compounds.
Compound exposure
Concentration ranges of MTX (Sigma-Aldrich, St. Louis, Missouri)
and TAA (Sigma-Aldrich) were selected based on plasma Cmax
values of effective doses reported in clinical studies and animal
models of fibrotic injury (Chilakapati et al., 2005; Shiozawa et al.,
2005) and at an estimated sinusoidal concentration (Ferslew and
Brouwer, 2014). For TAA, the plasma Cmax values were further
benchmarked against toxicity studies performed in vitro where
TAA did not elicit LDH release or evidence of cellular necrosis at
concentrations up to 50 mM in cultured primary rat HCs
(Hajovsky et al., 2012) to select the final concentration range.
TGF-b1 (Miltenyi Biotec Inc., San Diego, California), a well-
recognized potent, pro-fibrogenic cytokine that directly stimu-
lates collagen synthesis in HSCs (Leask and Abraham, 2004), was
evaluated at an estimated physiologically relevant concentration
(0.1 ng/mL) and at a concentration traditionally employed in
in vitro model systems (10 ng/mL) as a positive control (Fogel-
Petrovic et al., 2007). All dosing solutions were prepared immedi-
ately prior to addition to liver tissue constructs. Stock concentra-
tions of MTX prepared in 100% dimethyl sulfoxide (DMSO;
Sigma-Aldrich) were diluted in 3D Liver Tissue Medium
(Organovo, San Diego, California) to final concentrations of 0.1
and 1.0 lM (final DMSO concentration, 0.1%). A 25 mM dosing sol-
ution of TAA was prepared directly in the culture medium and
further diluted to prepare a 5.0 mM dosing solution. Lyophilized
TGF-b1 was reconstituted in Corning USP/EP Certified Sterile
WFI-Quality Water (Fisher Scientific, Pittsburgh, Pennsylvania)
according to the product data sheet recommendations and added
to the medium to prepare the 0.1 ng/mL and 10 ng/mL dosing
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solutions. To ensure vehicle consistency across treatment
groups, 100% DMSO was spiked into the TAA and TGF-b1 dosing
solutions and standard culture medium (vehicle control) such
that the final DMSO concentration was 0.1%. Liver tissues were
treated daily for either 7 or 14 days starting on the third day post-
printing.
Lactate dehydrogenase assay
Spent medium samples collected on alternate treatment days
were analyzed fresh for LDH activity using a commercially avail-
able colorimetric assay (Abcam, Cambridge, Massachusetts). The
assay was performed per the manufacturer’s instructions using a
CLARIOstar microplate reader (BMG Labtech, Germany) with
minor modifications. Briefly, a half area polystyrene high-bind
96-well plate (Sigma-Aldrich) was employed, allowing the vol-
umes of the kit reagents to be reduced by half. Samples were
diluted to obtain readings within the linear range of the NADH
standard curve corresponding to LDH activity between 1.0 and
100 mU/mL.
Albumin immunoassay
Spent medium samples from treatment days 1, 7, and 14 (ie, Tx1,
Tx7, and Tx14) were analyzed for albumin content by a plate
reader-based sandwich ELISA (Bethyl Laboratories, Montgomery,
Texas) per the manufacturer’s instructions with minor modifica-
tions as described above. Samples were tested at different dilu-
tions to obtain readings within the range of the standard curve
generated from Human Reference Serum (1.6–1200 ng/mL; Bethyl
Laboratories).
Cytokine measurements
Spent medium samples from select time points throughout the
exposure period were aliquoted and stored at 80 C until fur-
ther analysis. The levels of cytokines released into the medium
were assayed on the MESO QuickPlex SQ 120 Instrument using
the Meso Scale Discovery (MSD) V-PLEX Human Biomarker kit
(MSD, Rockville, Maryland), per the manufacturer’s instructions.
MSD Discovery Workbench software (version 4.0) was used
to generate a standard curve with a 4 parameter logistic fit and
1/y2 weighing (R2>0.998). Cytokine concentrations in unknown
medium samples were then interpolated from the standard
curve. Cytokine heat maps exhibiting cytokine concentrations
for each treatment relative to time-matched, vehicle-treated
control were constructed using the JMP statistical software
package Graph Builder (SAS Institute, Inc., Cary, North
Carolina).
Histology
At the conclusion of the study, a subset of bioprinted liver tis-
sues from each treatment group were formalin-fixed in a 2%
paraformaldehyde solution (ie, 2% paraformaldehyde, 10 mM
calcium chloride, 50 mM sucrose in phosphate buffered saline)
for 24 h at 4 C and transferred to 70% ethanol for 24 h. After
processing and embedding tissues, blocks were sectioned at a
5.0 lm thickness using a rotary microtome (Jung Biocut 2035;
Leica Microsystems, Buffalo Grove, Illinois). Sections were
stained with Gill 3 Formulation Hematoxylin (Ricca Chemical
Company, Arlington, Texas) and Eosin Y Solution, 1% Aqueous
(Electron Microscopy Sciences, Hatfield, Pennsylvania).
Additional slides were developed using Gomori’s One-Step tri-
chrome (American MasterTech, Lodi, California) to evaluate col-
lagen content. Slides were imaged using a Zeiss Axioskop
microscope (Zeiss, Jena, Germany) and acquired with a Zeiss
ICM-1 camera using Zen Pro software (blue edition).
RNA isolation and measurement of fibrosis-associated genes using
quantitative real-time PCR
At the conclusion of the study, tissue lysates were prepared for
each treatment group by homogenization in TRIzol Reagent
(ThermoFisher Scientific, Waltham, Massachusetts). Total RNA
was isolated by performing a phenol chloroform extraction/
phase separation facilitated by Phase Lock Gel Heavy (5 PRIME,
Inc., Gaithersburg, Maryland) and column purified using the
RNeasy Plus Mini Kit (Qiagen, Valencia, California) according to
the manufacturer’s protocol. RNA purity and yield was assessed
using the NanoDrop 1000 version 3.5.2 (ThermoFisher Scientific,
Wilmington, Delaware). RNA samples were reverse transcribed
with the High Capacity RNA-to-cDNA Kit following the manufac-
turer’s instructions (ThermoFisher Scientific). Real-Time qRT-
PCR was performed using TaqMan Universal PCR Master Mix
(ThermoFisher Scientific) and manufacturer recommended “Best
Coverage” TaqMan Gene Expression Assays (ThermoFisher
Scientific) for hypoxanthine guanine phosphoribosyltransferase
(HPRT; housekeeping), a-smooth muscle actin (ACTA2) and colla-
gen, type 1, a1 (COL1A1), two genes known to be up-regulated
during fibrogenesis. Triplicate reactions were carried out using a
7900HT Fast Real-Time PCR System with sample analysis per-
formed using ABI PRISM Sequence Detection System software
version 2.4 (ThermoFisher Scientific). Relative quantities (RQ)
were calculated for each gene of interest by normalizing to HPRT
and are represented as fold change relative to vehicle-treated
control for each set of treatments (n¼ 2).
Immunostaining
Deparaffinized, formalin-fixed normal native and untreated bio-
printed liver tissue sections harvested 60 h post-printing were
subject to heat-mediated antigen retrieval in 1X citrate buffer sol-
ution, pH 6.0 (Diagnostic BioSystems, Pleasanton, California) and
immunolabeled using primary antibodies against E-cadherin
(ab1416 [1:100], Abcam) and vimentin (ab8978 [1:100], Abcam) to
highlight the formation of cellular junctions and distribution of
NPCs within the tissues. Additional tissue sections were incu-
bated with primary antibodies against albumin (A6684 [1:500],
Sigma), CD31 (ab76533 [1:250], Abcam), desmin (ab15200 [1:200],
Abcam), and a-smooth muscle actin (a-SMA; ab7817 [1:200],
Abcam) to demarcate the compartmentalized architecture of bio-
printed liver and activation status of HSCs in a 3D context. A sub-
set of bioprinted liver sections obtained from tissues exhibiting
prominent features of fibrotic change with trichrome staining
compared to vehicle-treated control tissues (ie, 1.0 mM MTX and
25 mM TAA) were immunolabeled for collagen I (ab34710 [1:500],
Abcam), collagen IV (ab6586 [1:200], Abcam), vimentin, and
a-SMA to examine the prevalence and distribution of collagen
subtypes in the tissue constructs and migration/activation of
NPCs throughout the tissue constructs. Vehicle-treated control
tissue was used to assess tissue non-specific antibody staining
within the tissue constructs. A secondary antibody control was
also performed on successive bioprinted liver tissue sections as a
procedural control (Supplementary Fig. 1). ImageJ software
(Schneider et al., 2012) was used to quantitatively measure the
percent area covered by immunoreactive collagens I and IV in
three fields of view from representative tissue sections.
Statistical analysis
Unless otherwise noted, results are expressed as the mean of
4–5 replicates 6 standard deviation (SD). Replicates refer to the
same lot of bioprinted livers from a particular batch or print.
The bioprinting process affords high reproducibility from each
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batch of bioprinted tissues. Statistical significance of treatment-
induced differences relative to vehicle-treated control was
determined using a two-way or one-way analysis of variance
(ANOVA) where appropriate, with post hoc Dunnett’s multiple
comparisons test using GraphPad Prism version 6.0 (Graph Pad
Software, Inc., La Jolla, California). A P-value< .05 was consid-
ered statistically significant. Outliers were identified using
Grubbs’ test to identify samples that fell one SD outside of the
mean of the data (a¼ .05) using GraphPad Prism version 6.0
(Graph Pad Software).
RESULTS
Bioprinted Constructs Exhibit Key Features of Native Liver
Bioprinting is the automated fabrication of multicellular tissue
that mimics the three-dimensional (3D) architecture and com-
plexity of native tissue via the spatially defined deposition of
cells in a proprietary bio-ink (Fig. 1A and B). Culturing cells in
this 3D context facilitates the formation of parenchymal tissue
architecture and polarization of epithelial cell membranes as
evidenced by E-cadherin staining between parenchymal cells
that resembles in vivo tissue density and localization (Fig. 1C
and D). The punctate patterning and distribution of mesenchy-
mal marker vimentin is preserved in 3D bioprinted liver and
facilitates key heterotypic cell–cell interactions critical for sup-
porting phenotypic features of uninjured liver (Fig. 1E and F),
and sustained viability for at least 4 weeks post-printing
(Nguyen, et al., 2016). Tissues comprising cryopreserved primary
HCs, HSCs, and ECs were fabricated reproducibly on the mem-
branes of standard 24-well culture inserts, thus enabling the
use of this system to conduct routine in vitro toxicity testing
(Fig. 2A). During the initial 3-day culture period, bioprinted cells
coalesce and remodel to form a tissue-like construct with the
retention of parenchymal (HC) and non-parenchymal (NPC)
compartments. These compartments are illustrated with the
hepatocellular marker albumin and the NPC markers CD31 and
vimentin which stain ECs and HSCs, respectively (Fig. 2B). A pro-
portion of vimentin positive HSCs were observed both within
the NPC compartment and scattered throughout the parenchy-
mal compartment making key heterotypic contacts with HCs.
Hepatic Stellate Cells Exhibit a Quiescent-like Phenotype in a Three-
Dimensional Context
Hepatic stellate cells (HSCs) and their activation state within
the center of the tissue construct were tracked in 3D culture by
staining for desmin, an intermediate filament present in HSCs
(Puche et al., 2013; Schmitt-Graff et al., 1991) and a-SMA, a
marker of activated HSCs (Friedman, 2008). Prior to incorpora-
tion in 3D bioprinted tissues, HSCs were propagated through
multiple population doublings and serial passages in 2D culture.
HSCs typically reside in a quiescent state in uninjured liver but
undergo activation in response to injury or 2D culture (ie, cul-
ture activation on collagen or plastic surfaces) as demonstrated
by increased expression levels of activation markers, such as a-
SMA (Carpino et al., 2005; Friedman, 2008). When cultured in a
3D context, HSCs embedded within the tissue architecture
exhibited a more quiescent-like phenotype as illustrated by the
retention of desmin and lack of a-SMA positivity (Fig. 2C, merge;
white arrows). Whereas a majority of the HSCs embodied in the
tissue are desmin(þ), activated desmin(þ)/a-SMA(þ) HSCs were
noted mainly at the periphery of the tissue (ie, the apical capsu-
lar region and basolateral edge of the tissue in contact with the
culture medium and transwell membrane), consistent with a
typical culture-activated phenotype (data not shown) and previ-
ously reported observations (Nguyen et al., 2016).
Effects of Fibrogenic Agents on Markers of Hepatocellular Injury and
Function
Drug- or chemical-induced fibrosis is a complex and progressive
process that usually occurs as a result of chronic exposure to
low levels of compounds. To evaluate the culture model as a
platform for studying drug- and chemical-induced fibrosis,
FIG. 1. 3D bioprinted tissue recapitulates the tissue-like density and architecture of normal liver. (A) Transverse cross-sections of native human liver and (B) bioprinted
human liver tissue stained with H&E. (C and D) Formation of hepatocellular junctions is shown with E-cadherin and the mesenchymal marker (E and F) vimentin is
used to highlight distribution patterns within the parenchyma analogous to native liver. Scale bar¼50 mm.
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FIG. 2. 3D bioprinted tissue exhibits a compartmentalized architecture and maintains hepatic stellate cells in a quiescent-like phenotype. (A) Illustration of a trans-
verse cross-section of bioprinted tissue on a transwell insert comprising hepatocytes (HCs) and compartmentalized endothelial cells (ECs) and hepatic stellate cells
(HSCs). (B) The organization of non-parenchymal cells (NPCs) is depicted with CD31 and vimentin staining to mark ECs and HSCs, respectively. Albumin is used to
denote the hepatocellular compartment (HC). Scale bar¼100 mm, inset scale bar¼25 mm. (C) HSC activation status was examined using desmin (generic marker) and
a-SMA (activation marker). Quiescent HSCs are denoted with white arrows. Scale bar¼50 mm.
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bioprinted tissues were exposed to known fibrogenic agents,
MTX and TAA, for up to 14 days. MTX is a folate antagonist
effectively used to manage inflammatory disorders (ie, rheuma-
toid arthritis, psoriasis) at low doses for extended periods of
time. However, it is known to cause elevations in alanine ami-
notransferase (ALT) and fibrosis in a subset of patients over pro-
longed treatment periods (Lindsay et al., 2009; Maybury et al.,
2014). TAA is a prototypical fibrogenic agent extensively used in
rodent models to study the development of liver injury and fib-
rosis (Starkel and Leclercq, 2011).
During the course of the study, the tissues remained intact
macroscopically, with a marked dose- and treatment-dependent
reduction in tissue size noted for 1.0 mM MTX and TAA-treated
groups by treatment day 14 (Tx14; Fig. 3A). LDH release was
measured in the culture medium to assess the impact of repeated
exposure on tissue viability. During the initial 7-day exposure
period, LDH release for MTX- and TGF-b1-treated groups
remained consistent with vehicle control levels (Fig. 3B). Within
the same time period, elevations in LDH were observed for
25 mM TAA beginning at Tx3 (Fig. 3C). At later treatment time
points (>Tx9), both 0.1 mM and 1.0 mM MTX-treated groups
exhibited a time-dependent 2- to 3-fold increase in LDH release
relative to vehicle control (****P< .0001). TAA exhibited similar
trends at the lower concentration beginning on Tx5; however,
LDH release measured from the 25 mM TAA-treated group
exhibited a monophasic increase that peaked around Tx5
(****P< .0001) and then declined again by Tx11. These results
were further supported by parallel trends in ALT release at simi-
lar time points during the exposure period (Supplementary
Figure 2). By Tx4, elevations in ALT were noted for the 1.0 mM
MTX- and 5.0 mM TAA-treated groups and sustained for the
remainder of the treatment time course. A similar monophasic
increase in ALT release was noted for 25 mM TAA, peaking
around Tx4.
FIG. 3. Impact of fibrotic agents on biochemical markers of liver tissue viability and functionality. (A) Gross images of tissues following 14 days of treatment. Scale
bar¼2.5 mm. (B and C) LDH release during an extended 14-day treatment with MTX, TAA, and TGF-b1 (n¼9 for Tx1–Tx7, n¼5 for Tx9–Tx14). (D) Albumin production as
a measure of hepatocellular function is depicted at key time points during the treatment period (n¼5). Significance was determined using a one-way ANOVA with post
hoc Dunnett’s multiple comparisons test (*P< .05, **P< .01, ***P< .001, ****P< .0001).
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Albumin output was measured at time points defined by the
LDH results (ie, prior to elevations in LDH, mid-way through the
treatment period, and time points at which statistically signifi-
cant elevations in LDH were observed) during the exposure
period as a measure of hepatocellular function (Fig. 3D).
Albumin output (ng/mL/million cells) for most of the treatment
groups remained within vehicle-treated control levels during
the treatment time course with the exception of the 0.1 ng/mL
and 10 ng/mL TGF-b1 (Tx14 increased; *P< 0.05 and
*****P< 0.0001, respectively) and the 25 mM TAA (Tx7 and Tx14
decreased; ****P< .0001) treatment groups. The measured depre-
ciation in albumin output for 25 mM TAA at Tx7 and Tx14 com-
plements the LDH and ALT results (Fig. 3C and Supplementary
Fig. 2B, respectively) further suggesting a perturbation in tissue
function as a result of hepatocellular injury. Because TAA
requires CYP2E1-mediated bioactivation to elicit hepatotoxicity,
the expression of CYP2E1 was verified in untreated bioprinted
tissues spanning the timeframe of exposure used in the current
studies (Supplementary Fig. 3).
Evidence of Collagen Deposition in Tissues Treated With Fibrogenic
Agents
For complex disease processes such as fibrosis that lack early and
informative biomarkers, histological assessment remains the gold
standard for detecting and evaluating the progression of fibrotic
injury (Barker et al., 2011; Sebastiani and Alberti, 2006). In order to
assess the effects of compound treatment, a subset of tissues
from each treatment group were examined histologically.
Transverse cross-sections of formalin-fixed, paraffin embedded
tissues were stained with hematoxylin and eosin (H&E) to evalu-
ate overall cell and tissue morphology (Fig. 4). Distinct compart-
ments were evident within the tissue constructs with delineation
of HC and NPC compartments (Fig. 4B). Treatment with 1.0 mM
MTX (Fig. 4G) and TAA at both concentrations (Figs. 4D and E)
resulted in a compact and rounded mass of cells compared to the
vehicle-treated group (ie, approximate 50% reduction in tissue
size) suggesting possible cell death and tissue degeneration
(which was also supported by the biochemical data), ECM deposi-
tion, and enhanced contraction of tissue architecture. Invasion of
FIG. 4. H&E and trichrome staining reveals key features consistent with clinical fibrosis in bioprinted tissues following 14 days of treatment with select fibrogenic
agents. Representative sections of bioprinted liver treated with (A) 0.1% DMSO vehicle, (B) 0.1 and (C) 10 ng/mL TGF-b1, (F) 0.1 and (G) 1.0 mM MTX, and (D) 5.0 and (E)
25 mM TAA. (B and C) A circle is used to delineate the non-parenchymal (NPC) from the parenchymal (HC) compartments and white arrows denote the basolateral
edge of the tissue in contact with the transwell membrane. Collagen deposition was visualized (blue) in successive sections of bioprinted tissue stained with Gomori’s
trichrome. Entrapped hepatocytes (EH), nodular areas of collagen deposition (NF), pericellular fibrosis (PF; F and G inset, 150% enlarged), (G) yellow arrows denote bridg-
ing fibrosis. Scale bar¼100 mm. (F) Expression of fibrosis-associated genes at Tx7 and Tx14 in MTX-treated tissue.
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NPCs into the HC compartment was observed for all tissues
exposed to fibrogenic agents. For both TGF-b1-treated groups (Fig.
4B and C), the basal surface of the tissue in contact with the trans-
well membrane exhibited concentration-dependent differences in
the thickness of scar-like tissue (white arrows). This phenomenon
was also observed for the MTX- (Fig. 4F and G) and TAA-treated
(Fig. 4D and E) groups with a more extensive replacement of the
tissue with fibrous-scarring.
Gomori’s trichrome stain (Fig. 4) revealed stark differences
between vehicle-, TGF-b1-, MTX-, and TAA-treated tissues. In
the vehicle-treated control, there was faint evidence of collagen
deposition (blue) throughout the construct (Fig. 4A). TGF-b1
treatment caused diffuse areas of collagen deposition localized
to the NPC compartment (Fig. 4B; outlined), a dose-dependent
thickening of the basolateral edge of the tissue (Fig. 4B and C;
indicated with white arrows), and a generally preserved HC
mass, a histological outcome mirrored in the LDH data (Fig. 3).
MTX (0.1 mM) caused mild hepatocellular damage and evidence
of pericellular fibrosis (Fig. 4F; PF; inset 150% enlarged) that pro-
gressed with 1.0 mM MTX treatment to include areas of nodular
fibrosis (NF) and a compacted mass of cells separated by fibrotic
septae bisecting the hepatocellular compartment (Fig. 4G; yel-
low arrows). Treatment with TAA diminished the parenchymal
compartment in the tissues in a concentration-dependent man-
ner by 14 days, with entrapment of remaining HCs (Fig. 4D and
E; EH) and replacement of the parenchymal compartment with
extensive whorls of scar-like tissue. Preliminary analysis of two
fibrosis-associated genes, ACTA2 and COL1A1 in MTX-treated
tissues exhibited a 2- to 3-fold increase in expression relative to
vehicle-treated control by Tx14 concordant with histological
findings (Fig. 4H).
Cross-sections of tissues from treatment groups that exhib-
ited pronounced evidence of collagen deposition as evidenced
by Gomori’s trichrome staining were further examined immu-
nohistochemically for the prevalence of collagens I and IV and
the distribution and activation of HSCs within the tissue using
vimentin and a-SMA (Fig. 5). Relative to vehicle-treated control,
collagen production (Fig. 5A and B) was visually upregulated in
tissues treated with 1.0 mM MTX and 25 mM TAA with both col-
lagen subtypes most prevalent in the 25 mM TAA-treated tissue.
The average percent area of collagen in the 25 mM TAA-treated
group compared to vehicle-treated control was 25.784% versus
7.529% for collagen I and 29.832% versus 2.121% for collagen IV
(Fig. 5A vs B), respectively.
Whereas collagen I and collagen IV exhibit similar patterns
at first glance, closer examination shows distinguishing pat-
terns in the localization of greatest staining intensity. Collagen
I, positive areas were localized to the apical face of the tissue
(ie, capsular region) of the tissue (Fig. 5A; white arrow) and at
the basolateral edge of the tissue in contact with the transwell
membrane (Fig. 5A; yellow arrow). In addition, collagen I stain-
ing was prominent in the septae traversing the parenchymal
compartment, thicker ECM fibers present within the tissue con-
structs (outlined), and in areas of nodular fibrosis (NF) concord-
ant with collagen positive areas in Gomori’s trichrome-stained
sections (blue staining; Fig. 4). In comparison, collagen IV posi-
tive areas were mainly localized to the immediate periphery of
cells in the HC compartment with little to no staining of fibrillar
collagen (Fig. 5B; corresponding areas of collagen I- versus colla-
gen IV-stained sections are outlined). Similar to collagen I, colla-
gen IV was also prominent in nodular areas of collagen
deposition, particularly in the NPC compartment.
The distribution and patterning of vimentin in the tissue
constructs mirrors the results obtained from collagen
immunohistochemistry (IHC) and varies with treatment and the
degree of fibrotic injury (Fig. 5C). In the vehicle-treated group,
vimentin positivity appears as small punctate spindle shaped
areas with the greatest prevalence in the non-parenchymal
compartment and even distribution throughout the parenchy-
mal compartment (white arrows). Following 14 days of treat-
ment, vimentin transitions to a more extensive and diffuse
patterning throughout the tissue constructs (series of yellow
arrows) compared to vehicle-treated control, particularly in
areas corresponding to nodular areas of collagen deposition
(NF). In addition to measuring the distribution of NPCs within
the tissue constructs, the activation of HSCs in bioprinted liver
was also assessed by staining for a-SMA (Fig. 5D). Activated a-
SMA(þ) HSCs were mainly noted at the periphery of the tissue
in the vehicle-treated control (white arrow) with the minimal
activation of HSCs within the center of the tissue construct.
Treatment with fibrogenic agents resulted in an increase in
SMA(þ) HSCs in the center of the tissue (white arrows) and
altered distribution of the cells corresponding to areas of colla-
gen deposition. Overall, these histological features were consis-
tent with the upregulation of ACTA2 and COL1A1 relative to
vehicle-treated controls at Tx7 and Tx14 (Fig. 4H and
Supplementary Table 1).
Cytokine Profiles Are Indicative of a Fibrogenic State
Because inflammation is closely tied to fibrogenesis (Pellicoro
et al., 2014), the abundance of pro- and anti-inflammatory cyto-
kines (pg/mL) released into the culture medium from treated
tissues throughout the exposure period (ie, alternate treatment
days) was measured. A general decrease in cytokines starting at
Tx1 is apparent for all treatment groups including vehicle-
treated control (Supplementary Fig. 4). By Tx7, the initial spike
in cytokine production subsides (Supplementary Fig. 4) and
treatment-dependent differences become perceptible.
In order to assess treatment-dependent effects over time,
the fold change in cytokine levels relative to time-matched
vehicle-treated control was determined (Fig. 6). A subset of cyto-
kines depicted in Figure 6A changed consistently across repli-
cates and illustrate treatment- and concentration-dependent
effects over the course of the 14-day exposure period. Other
cytokines detected from the cytokine panel exhibited similar
trends although they were admittedly variable. During the ini-
tial treatment period (Tx1 and Tx3), deviations in the prevalence
of specific cytokines from vehicle-treated control are not readily
apparent with the exception of IL-13, an important inflamma-
tory mediator, in treated tissues (Fig. 6A; decreased). Starting at
Tx7, elevations in proinflammatory IL-6 were evident for 1.0 mM
MTX and both TAA-treated groups with slight elevations
observed for 0.1 mM MTX starting at Tx9. IL-6 regulates acute
phase response proteins in response to injury (Choi et al., 1994)
and in part, coincides with the biochemical data for MTX and
TAA (Fig. 3 and Supplementary Figure 2). Furthermore, a more
general decrease in cytokines observed starting at Tx7 with
25 mM TAA treatment, was concordant with the timeframe of
LDH and ALT release (Fig. 3C and Supplementary Fig. 2B), and
decreased albumin production at Tx7 and Tx14 (Fig. 3D) sug-
gesting tissue damage and perturbation of hepatocellular func-
tion. In comparison, the trends in cytokines observed with MTX
and TAA treatment were not evident for TGF-b1-treated tissues.
This difference in profiles is not entirely unexpected, consider-
ing the apparent absence of hepatocellular damage seen with
TGF-b1 treatment (Fig. 3) and the different mechanisms of
action of cytokine- versus xenobiotic-induced liver fibrosis.
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After the initial assessment of selected cytokines, additional
cytokine profiling was performed at Tx7 and Tx14 (Fig. 6B; cyto-
kines exhibiting consistent changes across replicates are
depicted). Measurement of cytokine levels at these time points
showed treatment- and time-dependent differences in acute
phase response, immunomodulatory, angiogenic, and chemo-
tactic cytokines. A Log2(Fold Change) of 2 or 2 was considered
statistically significant. IL-6 was significantly increased at Tx7
and Tx14 for 1.0 mM MTX and both TAA treatment groups con-
sistent with initial temporal observations from Figure 6A. Fms-
related tyrosine kinase-1 (Flt-1), involved in cell proliferation,
differentiation, and monocyte activation/recruitment
(Motomura et al., 2005), is statistically increased at Tx7 for
25 mM TAA-treated tissues and then returns to vehicle-treated
levels by Tx14. Monocyte chemotactic protein-1 (MCP-1),
involved in facilitating macrophage/monocyte infiltration to
perpetuate an adaptive response to continued insult (Baeck
et al., 2012), increases at Tx7 for 1.0 mM MTX and 5.0 mM TAA
treatment and continues to increase by Tx14 with the exception
of 25 mM TAA. Interestingly, the abundance of eotaxin, a media-
tor of inflammatory cell infiltration and recruitment, was signif-
icantly increased in the culture medium of tissues treated with
FIG. 5. Increased deposition of collagens I and IV and expression of vimentin and a-SMA in tissues exhibiting pronounced fibrogenic change. Tissues treated with 0.1%
DMSO vehicle, 1.0 mM MTX, and 25 mM TAA were further assessed immunohistochemically for (A) collagen I, (B) collagen IV, (C) vimentin, and (D) a-SMA. White and
yellow arrows denote the apical and basolateral edges of the tissue, respectively. Areas of fibrillar ECM deposition are outlined in successive collagen I and collagen IV
stained sections. Nodular areas of collagen deposition (NF). The percent area covered by collagens I and IV is depicted in the bottom left-hand corner of the photomi-
crographs. (C) Punctate areas of vimentin positivity in control tissue (white arrows) and diffuse patterning in treated tissue (yellow arrows). The black and white inset
accentuates the shift in vimentin patterning observed with treatment. (D) a-SMA(þ) HSCs were mainly noted at the periphery of the tissue in the vehicle-treated con-
trol (white arrows). Increased SMA(þ) HSCs in the center of treated tissues and altered distribution of the cells corresponding to areas of collagen deposition (white
arrows). Scale bar¼25 mm.
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FIG. 6. Subset of cytokines exhibiting treatment-dependent differences over time and at select treatment time points. (A) The upregulation (red) and downregulation
(green) of proinflammatory, immunoregulatory, and chemotactic cytokines relative to vehicle-treated control was represented in a heat map. (B) Samples collected at
mid (Tx7) and late (Tx14) treatment time points were profiled for additional cytokines and chemokines. Values outside the range of the standard curve or excluded via
Grubb’s outlier analysis are shaded grey.
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10 ng/mL TGF-b1 suggesting a possible direct-acting stimulation
of eotaxin expression in the absence of overt hepatocellular
injury (Matsukura et al., 2010).
DISCUSSION
Recently, liver fibrosis secondary to compound-induced liver
injury has become an interest to the Joint Research Centre (JRC)
and other regulatory organizations focused on adverse out-
comes (Ankley et al., 2010). Because fibrosis develops over time
from a sequence of complex and cumulative interactions
between HCs and NPCs, it has proven challenging to model
using standard in vitro and preclinical in vivo models. The devel-
opment of an effective Adverse Outcome Pathway framework
depends on the employment of models that overcome these
translational challenges and provide a test bed that is multicel-
lular, compatible with chronic exposure testing regimens, and
able to reveal a full spectrum of relevant outcomes from initia-
tion through progression, including biochemical, genomic, and
histologic endpoints (Van de Bovenkamp et al., 2007). Here we
evaluated the potential of a novel bioprinted in vitro tissue
model of human liver to model compound-induced fibrosis.
This approach represents a significant innovation in the study
of progressive liver injury and in vitro toxicity testing, as it
addresses many of the shortcomings associated with traditional
models.
The constitutive activation of HSC monocultures has been a
significant barrier in the in vitro assessment of potential fibro-
genic agents, as compound-related effects are confounded by
the culture-activated HSC phenotype. Whereas there have been
some recent advances in the study of hepatic fibrosis in vitro
using precision cut liver slices (PCLS) or spheroids (Leite et al.,
2016; Thiele et al., 2015; Van de Bovenkamp et al., 2007; Westra
et al., 2016), there still exist limitations in the application of
these platforms to understand the progression of events under-
lying fibrogenesis. PCLS have a short life span ex vivo (general-
ly<1 week) and develop early onset fibrogenic changes,
irrespective of treatment, which may confound the interpreta-
tion of a causal relationship after compound exposure (Westra
et al., 2016). As such, chronic exposure studies aimed at model-
ing progressive fibrogenic features over weeks to months have
not been feasible with PCLS. Finally, whereas the fixed configu-
ration of the cells comprising each slice preserves the normal
tissue architecture initially, the ability to tease apart the roles of
the different cell types is severely limited. Bioprinting is an effi-
cient and reproducible means of establishing key architectural
relationships between cells and preserving tissue-level func-
tions over prolonged periods of time (Nguyen et al., 2016). The
3D nature and substantial biomass of the model enable histo-
logical assessment of treated liver tissues, which remains the
diagnostic gold standard for the accurate detection and staging
of fibrosis (Sebastiani and Alberti, 2006). The unique compart-
mentalized architecture of bioprinted tissues compared to other
3D models, such as spheroids (Leite et al., 2016), facilitates the
temporal assessment of progression by revealing specific pat-
terns of collagen deposition that are analogous to patterns
described in human biopsy samples.
Importantly, the incorporation of HSCs into 3D bioprinted
tissue re-establishes a quiescent-like phenotype and thus
uniquely enables the model to be used in the assessment of
compound effects on early fibrogenic processes—something
that has not been feasible to date using conventional
approaches. This phenomenon is consistent with the outcome
of elegant fate-mapping studies in mice that demonstrated a
subset of HSCs are able to revert to a quiescent-like phenotype
(Kisseleva et al., 2012) during the resolution of fibrotic injury.
HSCs that have been previously activated exhibit a primed phe-
notype with rapid and robust patterns of reactivation in
response to subsequent injury (Kisseleva et al., 2012; Taghdouini
et al., 2015). This observation could explain the accelerated fibro-
genic features observed in the current study, compared to the
clinical setting in which fibrosis can take months or even years
to develop. Regardless of whether the desmin(þ)/a-SMA()
HSCs represent quiescent or inactivated HSCs, the results pre-
sented herein demonstrate their clear capacity to mount a
measurable and progressive response to fibrogenic insults.
Following 14 days of exposure, the extent of LDH release and
time to peak release was compound-, concentration-, and time-
dependent. The monophasic increase in LDH release and subse-
quent return to vehicle-treated levels for 25 mM TAA most likely
reflects the outcome of prior hepatocellular damage, as sup-
ported by the corresponding loss of albumin production and
decrease in ALT release. In contrast, TGF-b1 treatment did not
elicit elevations in LDH release during the entire exposure
period. TGF-b1 is a well-established pro-fibrogenic mediator,
directly triggering the activation of HSCs and synthesis of ECM
(Leask and Abraham, 2004). Albumin production was not signifi-
cantly perturbed with the exception of the TGF-b1 (increased
production) and the 25 mM TAA (decreased production) treat-
ment groups. Whereas previous studies have reported TGF-b1
inhibits albumin RNA and protein synthesis in primary HCs, it
should be noted that these studies were conducted in HC mono-
cultures (Busso et al., 1990). We hypothesize the lack of concord-
ance may reflect TGF-b1-induced secretion of ECM proteins and
other factors by the NPC compartment that further support HC
function in the absence of overt injury. Taken together, these
data demonstrate that the exposure conditions described
herein are able to produce the mild/moderate HC injury associ-
ated with low-concentration, chronic exposure, which sets the
stage for the development and detection of more complex
adverse outcomes such as fibrosis.
Histological assessment of treated tissues revealed the ini-
tiation and progression of fibrogenic processes in response to
insult. The degree of collagen deposition in treated tissues cor-
related with biochemical evidence of hepatocellular damage,
with 1.0 mM MTX and 5.0 and 25 mM TAA-treated tissues exhib-
iting a disrupted architecture with prevalent collagen deposits
that progressed to a scar-like matrix and displaced the HC com-
partment over time. Interestingly, patterns of collagen deposi-
tion and tissue injury observed in the MTX- and TAA-treated
groups were analogous to those reported in clinical biopsy sam-
ples of MTX-induced fibrosis and preclinical animal models of
TAA exposure (Müller et al., 1988; Osuga et al., 2015), which sug-
gests the model may serve as a translational tool for mechanis-
tic and interventional studies involving fibrogenic agents and
modulators. Changes in ACTA2 and COL1A1 expression, further
confirmed the progression- and concentration-dependent
nature of the fibrogenic response, particularly in MTX-treated
tissues. The treatment-induced mobilization of NPCs and
activation of HSCs within the tissue were consistent with find-
ings from published clinical studies of progressive fibrosis
(Attallah et al., 2007; Veidal et al., 2011). Whereas future studies
will expand the genomic, proteomic, and histologic characteris-
tics of the model during progressive fibrotic injury, these initial
observations provide encouraging evidence that the model has
translational utility.
Interestingly, compound-dependent fibrogenic responses
were elicited in the absence of liver resident macrophages.
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While inflammation typically precedes or accompanies liver fib-
rosis and is recognized as a driver of fibrogenesis (Czaja, 2014;
Pellicoro et al., 2014), the precise role of KCs in mediating this
process remains elusive. This is largely due to the inability to
target specific macrophage subpopulations (Tacke and
Zimmermann, 2014), a question which can be addressed using
this model. We anticipate that KCs will play an important tol-
erogenic role in attenuating the tissue response during early
exposure to pro-fibrogenic agents (Ju and Pohl, 2005). We sought
to validate the established 3D liver model, which consists of two
key NPC constituents, namely, ECs and HSCs, but also is amena-
ble to modifications in cellular composition. These studies lay
the foundation for the future assessment of the role of KCs and
other cell types relevant to the response (ie, sinusoidal endothe-
lial cells) in exacerbating or remediating tissue injury and their
impact on fibrogenic outcome.
Cytokine profiles differed between early and late time points
of exposure to fibrogenic agents, which likely reflects the modu-
latory role(s) of specific cytokines that mark liver injury and
influence fibrogenic outcomes in response to insult. The induc-
tion of proinflammatory cytokines during early exposure (Tx1–
Tx7) mimics some features of the classic wound-healing
response (Pellicoro et al., 2014), with a surge in the production of
proinflammatory cytokines that drive tissue remodeling and
regeneration and may aid in the formation of a cohesive tissue-
like mass after bioprinting. It is likely that both the HSC and EC
components of the bioprinted tissues contributed to the eleva-
tions of IL-6 and IL-8, which enhance EC survival, proliferation,
angiogenesis, and recruitment of inflammatory cells during
wound healing (Qazi et al., 2011). IL-1 is also rapidly released in
response to tissue damage (Gieling et al., 2009) and could explain
the transient increase in IL-1b early in the exposure period.
When cytokines approached steady-state levels in vehicle-
treated tissues (10 days post-printing) treatment-dependent
spikes in proinflammatory cytokines were detected. Increased
chemotactic cytokines, such as MCP-1, at later time points for
some treatment groups suggest an adaptive shift in response to
persistent tissue stress/injury that results in recruitment of
inflammatory cells to the site of damage (Baeck et al., 2012).
Observed differences in the cytokine profiles in TGF-b1- versus
compound-treated tissues is likely due to mechanistic differen-
ces between the TGF-b1 response (little to no hepatocellular
injury) and compound-induced responses to hepatocellular
injury and/or the transient nature of cytokine profiles. The
global decline in cytokine production observed at 25 mM TAA by
Tx14 was consistent with the decline in viability and functional-
ity for that time point. Significant differences in cytokine levels
among treatment groups were not noted during early exposure,
likely due to their masking by the observed wound-healing
response post-fabrication. Furthermore, cellular interactions
and cross-talk that occur during tissue formation could influ-
ence susceptibility or magnitude of response to particular
insults. Future studies will examine alterations in response pro-
files in maturing (3–5 days old) versus matured (7–10 days old)
tissues. Nonetheless, the cytokine data in conjunction with the
gene expression and histological data supports the hypothesis
that these tissues are actively engaging in fibrogenic processes
in response to compound-induced injury.
In summary, the outcomes from these studies support con-
tinued development of 3D bioprinted human tissues as in vitro
surrogates for studying compound-induced liver fibrosis. Future
studies will provide new insights into early initiating and adap-
tive events underlying fibrogenic responses, help identify both
common and distinct pathways of compound-induced effects,
and improve compound risk assessment. While there exist a
number of challenges towards developing effective treatment
strategies (ie, causation, stage of fibrotic injury, co-morbidities),
these studies bridge a critical gap that could inform effective
therapeutic approaches (ie, novel biomarkers and interven-
tional strategies) for treatment at early and late stages of fibro-
genesis during which different hepatic cell types may be
involved and targeted to prevent or reverse liver fibrosis.
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